Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | ROS1 | P08922 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1184463 | 0.86 | MMP12 (0.47) | CDK5ROS1ACVR1LRRK2EPHX2 | |
| SCHEMBL29783299 | 0.86 | MMP12 (0.47) | CDK5ROS1ACVR1LRRK2EPHX2 | |
| SCHEMBL16588451 | 0.80 | EPHX2 (0.47) | CDK5ROS1ACVR1LRRK2EPHX2 | |
| SCHEMBL1183823 | 0.79 | TGM2 (0.53) | CDK5LRRK2PDE3BPDE3ALMNA | |
| SCHEMBL1186060 | 0.79 | SRD5A1 (0.50) | CDK5LRRK2PDE3BPDE3AKDM4E | |
| SCHEMBL1184405 | 0.79 | TGM2 (0.53) | LRRK2PDE3BPDE3APKMPARP1 | |
| SCHEMBL1185219 | 0.79 | KMT2A (0.54) | CDK5LRRK2PDE3BPDE3APARP1 | |
| SCHEMBL1183750 | 0.78 | PDE3B (0.74) | CDK5LRRK2PDE3BPDE3AALDH1A1 | |
| SCHEMBL6866393 | 0.78 | MEN1 (0.39) | PDE3BPDE3AALDH1A1KDM4EPKM | |
| SCHEMBL433753 | 0.78 | PKM (0.58) | EPHX2PDE3BPDE3AMMP12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270695-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4277897-A1 | FUSED AZEPINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Chengdu Anticancer Bioscience, Ltd. (CN) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022152097-A1 | FUSED AZEPINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Chengdu Anticancer Bioscience, Ltd. (CN) | 2022-07-21 | — | — | WO | disclosed |
| EP-1399448-B1 | IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2004-12-01 | — | — | EP | disclosed |
| EP-1399448-A1 | IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| US-6686352-B2 | USEFUL AS COGNITIVE ENHANCER OR FOR THERAPY OF COGNITIVE DISORDERS LIKE ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030055042-A1 | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives | F. HOFFMANN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-03-20 | — | — | US | disclosed |
| WO-2002094834-A1 | IMIDAZO [1,5-A] PYRIMIDO [5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270695-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | CDK5 581/4885ROS1 3071/4885ACVR1 4492/4885 |
| US-20030055042-A1 | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives | GALR1, GALR2, ADRA1A | CDK5 2328/4885ROS1 3155/4885ACVR1 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.